| Target Price | $20.40 |
| Price | $12.70 |
| Potential |
60.63%
register free of charge
|
| Number of Estimates | 5 |
|
5 Analysts have issued a price target Seres Therapeutics Inc 2026 .
The average Seres Therapeutics Inc target price is $20.40.
This is
60.63%
register free of charge
$23.10
81.89%
register free of charge
$6.06
52.28%
register free of charge
|
|
| A rating was issued by 10 analysts: 7 Analysts recommend Seres Therapeutics Inc to buy, 3 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Seres Therapeutics Inc stock has an average upside potential 2026 of
60.63%
register free of charge
|
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Sep 24 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | May 08 2025 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Mar 20 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| Canaccord Genuity |
Locked
➜
Locked
|
Locked | Nov 14 2024 |
| Chardan Capital |
Locked
➜
Locked
|
Locked | Nov 13 2024 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Oct 24 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Sep 24 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Mar 20 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
Canaccord Genuity:
Locked
➜
Locked
|
Nov 14 2024 |
|
Locked
Chardan Capital:
Locked
➜
Locked
|
Nov 13 2024 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Oct 24 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


